- Home
- ECAT vs BCRX Comparison
ECAT vs BCRX Comparison
Compare ECAT & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECAT
- BCRX
- Stock Information
- Founded
- ECAT 2021
- BCRX 1986
- Country
- ECAT United States
- BCRX United States
- Employees
- ECAT N/A
- BCRX N/A
- Industry
- ECAT Trusts Except Educational Religious and Charitable
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ECAT Finance
- BCRX Health Care
- Exchange
- ECAT Nasdaq
- BCRX Nasdaq
- Market Cap
- ECAT 1.7B
- BCRX 1.7B
- IPO Year
- ECAT N/A
- BCRX 1994
- Fundamental
- Price
- ECAT $15.96
- BCRX $9.66
- Analyst Decision
- ECAT
- BCRX Buy
- Analyst Count
- ECAT 0
- BCRX 8
- Target Price
- ECAT N/A
- BCRX $16.75
- AVG Volume (30 Days)
- ECAT 278.6K
- BCRX 3.5M
- Earning Date
- ECAT 01-01-0001
- BCRX 08-04-2025
- Dividend Yield
- ECAT 9.20%
- BCRX N/A
- EPS Growth
- ECAT N/A
- BCRX N/A
- EPS
- ECAT 2.39
- BCRX N/A
- Revenue
- ECAT N/A
- BCRX $503,485,000.00
- Revenue This Year
- ECAT N/A
- BCRX $39.04
- Revenue Next Year
- ECAT N/A
- BCRX $13.26
- P/E Ratio
- ECAT $7.15
- BCRX N/A
- Revenue Growth
- ECAT N/A
- BCRX 41.67
- 52 Week Low
- ECAT $14.02
- BCRX $6.02
- 52 Week High
- ECAT $17.30
- BCRX $11.31
- Technical
- Relative Strength Index (RSI)
- ECAT 51.41
- BCRX 38.90
- Support Level
- ECAT $15.52
- BCRX $9.72
- Resistance Level
- ECAT $15.98
- BCRX $10.06
- Average True Range (ATR)
- ECAT 0.19
- BCRX 0.31
- MACD
- ECAT -0.04
- BCRX -0.17
- Stochastic Oscillator
- ECAT 40.70
- BCRX 3.09
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.